Return to School Practices for Pediatric Hematopoietic Cell Transplant Recipients During COVID-19 Pandemic
Abstract
Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk
According to the results of a study presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO), graft vs host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (PTCy) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) does not appear to be associated with an increased risk in bacterial, viral, or fungal infections.
Life Expectancy Still Lower for Blood or Marrow Transplant Recipients
While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study found.
FDA approves belumosudil for chronic graft-versus-host disease
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Efficacy was evaluated in KD025-213 (NCT03640481), a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
FDA NEWS RELEASE
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Abstract
Major Health Care Professional Organizations Call for COVID-19 Vaccine Mandates for All Health Workers
Groups include American Medical Association, American Nurses Association, American Academy of Pediatrics, Association of American Medical Colleges, and National Association for Home Care and Hospice
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination
Key Points
Severe exacerbation of underlying hematologic conditions can occur within 1 to 4 days after dose 2 of a 2-dose SARS-CoV-2 vaccine series.
A mild exacerbation after dose 1 and/or a history of vaccine-related adverse events may portend a more serious event after dose 2.
New target to prevent leukaemia in Down’s syndrome children
Researchers have mapped for the first time how and where leukaemia develops in children with Down’s syndrome, it has been announced.
Researchers at the Princess Margaret Cancer Centre in Toronto, Canada, say their research could eventually help doctors prevent pre-leukaemia in children with Down’s syndrome, and even have potential to transform cancer care in other children.